Evaluation of extracorporeal shock wave therapy in Peyronie’s disease



      To evaluate the results of extracorporeal shock wave therapy (ESWT) in patients with Peyronie’s disease.


      This study included 42 patients (mean age 55.4 years, range 32 to 72, SD 9.92) with Peyronie’s disease. The mean duration of disease was 16.5 months (range 3 to 60, SD 13.31). Before treatment, the degree of angulation was assessed artificially by injection of 10 to 20 μg alprostadil, and Polaroid photographs were taken. Patients were also questioned about pain on erection, whether sexual intercourse was possible, and the quality of erections. All were initially treated with three sessions of ESWT (3000 shock waves). After three sessions, patients who believed that improvement had resulted or who wanted to undergo additional treatment went on to have further sessions. The mean duration of follow-up was 5.9 months (range 2 to 18, SD 4.4), after which the results were analyzed.


      Those who believed that improvement in angulation had resulted were asked to provide Polaroid photographs to assess the improvement objectively. Six (14%) said that they had excellent results, 21 (50%) had significant improvement, 7 (17%) had slight improvement, and 8 (19%) had no change. Of the 25 who had pain on erection before treatment, 21 (84%) reported complete or near complete relief after treatment. Five patients said that the quality of the erections had improved after treatment. Eight patients complained of mild and one of severe pain during or immediately after treatment; 2 of these 9 patients had both pain and bruising.


      The initial results with ESWT are promising, with minimal complications. The long-term results need to be evaluated.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Dunsmuir WD, and Kirby RS: Francois de la Peyronie (1678–1747): the man and the disease he described. Br J Urol 78: 613–622, 1996

      2. Benson GS, and Boileau MA: The penis: sexual function and dysfunction, in Gillenwater JY (Ed): Adult and Paediatric Urology, 3rd ed. New York, Mosby, 1996, pp 1951–1996

        • Hussain J.
        • Lynn N.N.K.
        • Jones D.K.
        • et al.
        Extra corporeal shock wave therapy in the management of Peyronie’s disease.
        Br J Urol. 2000; 86: 466-468
        • Abdel-Salam Y.
        • Budair Z.
        • Renner C.
        • et al.
        Treatment of Peyronie’s disease by extra corporeal shockwave therapy.
        J Endourol. 1999; 13: 549-552
        • Lebret T.
        • Herve J.M.
        • Lugagne P.M.
        • et al.
        Extracorporeal lithotripsy in the treatment of Peyronie’s disease.
        Prog Urol. 2000; 10 ([in French]): 65-71
        • Colombo F.
        • Serrago M.
        • Esposito N.
        • et al.
        Shock waves in La Peyronie’s disease.
        J Urol. 1998; 159: 119
        • Colombo F.
        • Baroni P.
        • Serrago M.
        • et al.
        Shock waves in La Peyronie’s disease.
        Eur Urol. 1997; 35: 124
        • Gianneo E.
        • Nespoli R.
        • Conti G.
        • et al.
        La Peyronie’s disease (PD) and extracorporeal shock wave therapy.
        J Urol. 1999; 161: 205
        • Hamm R.
        • McLarty E.
        • Ashdown J.
        • et al.
        Peyronie’s disease—the Plymouth experience of extra corporeal shockwave treatment.
        Br J Urol. 2001; 87: 849-852
        • Hauck E.W.
        • Altinkilic B.M.
        • Ludwig M.
        • et al.
        Extracorporeal shockwave therapy in the treatment of Peyronie’s disease.
        Eur Urol. 2000; 38: 663-670
      3. Michel MS, Braun P, Sazova O,et al: Shock-wave therapy for the treatment of Peyronie’s disease: first clinical investigation for the objective determination of deviation improvement by means of artificial erection. J Urol 161(suppl): 262, 1999

        • Butz M.
        • Teichert H.M.
        Treatment of Peyronie’s disease (PD) by extracorporeal shockwaves (ESW).
        J Urol. 1998; 159: 118
        • Kelami A.
        Autophotography in evaluation of functional penile disease.
        Urology. 1983; 21: 628-629
        • Devine Jr, C.J.
        • Somers K.D.
        • Jordan S.G.
        • et al.
        J Urol. 1997; 157: 285-290
        • Godec C.J.
        • Van Beck A.L.
        Peyronie’s disease is curable—is it also preventable?.
        Urology. 1983; 21: 257-259
        • Hinman Jr, F.
        Peyronie’s disease.
        Prog Reprod Biol Med. 1983; 9: 5-12
        • Gelbard M.
        • Dorey F.
        • James K.
        The natural history of Peyronie’s disease.
        J Urol. 1990; 144: 1376-1379
        • Amin Z.
        • Patel U.
        • Friedman E.P.
        • et al.
        Colour Doppler and duplex ultrasound assessment of Peyronie’s disease in impotent men.
        Br J Radiol. 1993; 66: 398-402
        • Stecker J.
        • Devine C.
        Evaluation of erectile dysfunction in patients with Peyronie’s disease.
        J Urol. 1984; 132: 680-681
        • Smith B.H.
        Subclinical Peyronie’s disease.
        Am J Clin Pathol. 1969; 52: 385-390
        • Hasche-Klunder R.
        Treatment of Peyronie’s disease with para-aminibenzoacidic potassium (POTOBA).
        Urologe A. 1978; 17: 224-227
        • Ralph D.J.
        • Brooks M.
        • Bttazzo G.
        The treatment of Peyronie’s disease with tamoxifen.
        Br J Urol. 1992; 70: 648-651
        • Akkus E.
        • Carrier S.
        • Rehman J.
        • et al.
        Is colchicine effective in Peyronie’s disease? A pilot study.
        Urology. 1994; 44: 291-295
        • Rehman J.
        • Benet A.
        • Melman A.
        Use of intralesional verapamil to dissolve Peyronie’s plaque.
        Urology. 1998; 51: 620-626
        • Gholami S.S.
        • Lue T.F.
        Peyronie’s disease.
        Urol Clin North Am. 2001; 28: 377-390
      4. Jordan GH, Schlossberg SM, and Devine CJ: Surgery of the penis and urethra, in Walsh PC, Retik AB, Vaughan ED Jr, et al (Eds): Campbells’ Urology, 7th ed. Philadelphia, WB Saunders, 1998, vol 3, pp 3316–3394

        • Haupt G.
        • Chvapil M.
        Effect of shock waves on the healing of partial thickness wounds in piglets.
        J Surg Res. 1990; 49: 45-48

      Linked Article